Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Rating of “Reduce” from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been given an average recommendation of “Reduce” by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $14.00.

A number of equities research analysts recently commented on the stock. Piper Sandler cut shares of Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 target price for the company. in a research report on Thursday, January 8th. HC Wainwright downgraded shares of Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price for the company. in a research note on Thursday, January 8th. UBS Group reaffirmed a “neutral” rating and set a $14.00 price target (down from $20.00) on shares of Ventyx Biosciences in a research report on Thursday, January 8th. Lifesci Capital reiterated a “market perform” rating and set a $14.00 price objective on shares of Ventyx Biosciences in a report on Thursday, January 8th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $14.00 price objective on shares of Ventyx Biosciences in a research report on Thursday, January 8th.

Ventyx Biosciences Stock Performance

VTYX stock opened at $14.00 on Thursday. Ventyx Biosciences has a one year low of $0.78 and a one year high of $25.00. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -9.33 and a beta of 1.26. The firm has a 50-day simple moving average of $13.53 and a two-hundred day simple moving average of $8.69.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan sold 47,345 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. This trade represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Nuss sold 12,675 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider owned 489,481 shares in the company, valued at $3,778,793.32. The trade was a 2.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 14.49% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of VTYX. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ventyx Biosciences during the fourth quarter worth $31,000. Hudson Bay Capital Management LP acquired a new position in shares of Ventyx Biosciences in the 2nd quarter valued at $34,000. Engineers Gate Manager LP purchased a new position in Ventyx Biosciences in the 2nd quarter worth $42,000. Persistent Asset Partners Ltd purchased a new position in Ventyx Biosciences in the 3rd quarter worth $51,000. Finally, Jump Financial LLC acquired a new stake in Ventyx Biosciences during the 2nd quarter worth about $53,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.